GERMANTOWN, Md., July 13, 2023 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced the appointment of Elliot Maltz as Chief Financial Officer, effective September 1, 2023. Mr. Maltz succeeds Mr. Neil Reithinger, who is resigning following years of dedicated service and will remain with the Company until he completes his transition of duties, through September 1, 2023.
Mr. Maltz brings 16 years of accounting and corporate finance experience working with public and private companies, specializing in the biotechnology, medical device and manufacturing industries. Mr. Maltz, previously served as the Chief Financial Officer of Gelesis, Inc., a commercial stage biotherapeutics company, since May 2021 and as its Treasurer since May 2015. As Chief Financial Officer, Mr. Maltz led numerous fundraising and operational initiatives, including the efforts to take Gelesis, Inc. public through a SPAC merger in January 2022, whereupon he became the Chief Financial Officer and Treasurer of Gelesis Holdings, Inc. Prior to his appointment as the Chief Financial Officer, Mr. Maltz was Gelesis, Inc.’s Vice President of Finance and previously served as its Corporate Controller. Prior to joining Gelesis, Inc., Mr. Maltz served as an external auditor at Deloitte & Touche LLP from January 2007 to April 2013 and as a manager of the technical accounting and SEC reporting function at Sapient Corp. from April 2013 to March 2014. Mr. Maltz received a B.S. in Business Finance from Elon University and is a licensed CPA in the state of Massachusetts.
Vered Caplan, CEO of Orgenesis, stated, “I am honored to announce the appointment of Elliot Maltz as Chief Financial Officer, which is especially timely as we enter the next phase of our growth. Elliot brings extensive corporate finance and capital markets experience. We look forward to his insights and guidance on our corporate strategy and financial planning, as well as his involvement in helping maintain the highest levels of corporate governance. The Company and Board of Directors would also like to express our sincere gratitude and appreciation to Neil Reithinger for his significant contributions over the years.”
About Orgenesis
Orgenesis is a global biotech company that has been committed to unlocking the potential of decentralized cell and gene therapies (CGTs) since 2012. Orgenesis established the POCare Network in 2020 to bring academia, hospitals, and Industry together to make these innovations more affordable and accessible to patients. In 2022, the POCare Services business unit responsible for developing and managing the decentralized POCare Centers and proprietary OMPULs was formed. Orgenesis will continue to focus on advancing to market through various partnerships its CGTs to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. Additional information about the Company is available at: www.orgenesis.com.
